Medicilon grants service recognition award to Revolution Medicines
Research services provider Medicilon has awarded its 'Excellence in Client Partnership Award' to Revolution Medicines following a site visit to its Shanghai R&D facility.
Medicilon, a provider of drug discovery and development services, presented its 'Excellence in Client Partnership Award' to Revolution Medicines, a clinical-stage precision oncology company. The presentation took place during a visit by Revolution Medicines representatives to Medicilon’s Nanhui R&D Center in Shanghai.
The award acknowledges the ongoing collaborative efforts between the two companies in the field of drug discovery. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research division, hosted the visiting delegation, which included Dr. Yang Liu and Dr. Kristof Pota from Revolution Medicines.
For Medicilon, the recognition serves as a formal acknowledgment of its strategic partnerships within the biopharmaceutical sector. These collaborations are essential for the company as it maintains its drug discovery pipeline for international clients. The meeting also provided an opportunity for the parties to review current project statuses and technical workflows at the research site.